Meropenem Dosing Considerations in End-Stage Renal Disease

Introduction to Meropenem Dosing

• The American College of Clinical Pharmacology recommends administering meropenem after hemodialysis sessions to facilitate directly observed therapy and avoid premature drug removal, as all antituberculosis and antimicrobial medications should be given after such sessions 1, 2

Post-Dialysis Administration

• The Infectious Diseases Society of America suggests that post-dialysis dosing prevents the dialysis machine from removing the drug before it can exert therapeutic effect, which is crucial for maintaining efficacy 1, 2

Pharmacokinetic Rationale

• The European Renal Association warns that neurotoxicity risk increases when meropenem trough concentrations exceed 64 mg/L, and renal failure is the primary risk factor for beta-lactam accumulation 4
• The Critical Care society notes that approximately two-thirds of ICU patients experience significant neurological deterioration when free minimum concentration normalized to MIC exceeds 8 4

Monitoring and Dosing

• The National Kidney Foundation recommends keeping trough concentrations below 64 mg/L to minimize neurotoxicity risk, and targeting a free minimum concentration to MIC ratio (fCmin/MIC) of less than 8 4
• The Critical Care society suggests monitoring trough levels if available, to prevent neurotoxicity while maintaining efficacy 4

Administration Timing

• The American College of Clinical Pharmacology advises against administering meropenem before dialysis, as this wastes drug and reduces efficacy 1, 2